MACULAR NEOVASCULARIZATION IN A CASE OF LATE-ONSET RETINAL DEGENERATION TREATED WITH AFLIBERCEPT.

Q3 Medicine Retinal Cases and Brief Reports Pub Date : 2024-09-01 DOI:10.1097/ICB.0000000000001439

Durga Ganesh, Giulia Corradetti, Srinivas R Sadda

{"title":"MACULAR NEOVASCULARIZATION IN A CASE OF LATE-ONSET RETINAL DEGENERATION TREATED WITH AFLIBERCEPT.","authors":"Durga Ganesh, Giulia Corradetti, Srinivas R Sadda","doi":"10.1097/ICB.0000000000001439","DOIUrl":null,"url":null,"abstract":"Purpose: To describe the outcomes from treatment of macular neovascularization in an eye affected by late-onset retinal degeneration.Methods: A 72-year-old female patient presented with a history of decreased vision since several years. The patient was previously diagnosed with age-related macular degeneration and treated with anti-vascular endothelial growth factors.Results: Clinical examination of the retina and ultra-widefield color fundus photographs showed extensive atrophy in both eyes. The left eye showed macular neovascularization on fluorescein angiography, subretinal fluid on optical coherence tomography, and correspondent hemorrhages on the color fundus photography. Aflibercept anti-vascular endothelial factor treatment was used to treat the macular neovascularization in the left eye.Conclusion: We report a case of genetically confirmed late-onset retinal degeneration (heterozygous pathogenic mutation p.Ser163Arg in one C1QTN5 allele) with advanced degeneration of the retina complicated by macular neovascularization, which responded well to treatment with a single aflibercept injection.","PeriodicalId":53580,"journal":{"name":"Retinal Cases and Brief Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retinal Cases and Brief Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ICB.0000000000001439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To describe the outcomes from treatment of macular neovascularization in an eye affected by late-onset retinal degeneration.

Methods: A 72-year-old female patient presented with a history of decreased vision since several years. The patient was previously diagnosed with age-related macular degeneration and treated with anti-vascular endothelial growth factors.

Results: Clinical examination of the retina and ultra-widefield color fundus photographs showed extensive atrophy in both eyes. The left eye showed macular neovascularization on fluorescein angiography, subretinal fluid on optical coherence tomography, and correspondent hemorrhages on the color fundus photography. Aflibercept anti-vascular endothelial factor treatment was used to treat the macular neovascularization in the left eye.

Conclusion: We report a case of genetically confirmed late-onset retinal degeneration (heterozygous pathogenic mutation p.Ser163Arg in one C1QTN5 allele) with advanced degeneration of the retina complicated by macular neovascularization, which responded well to treatment with a single aflibercept injection.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用 aflibercept 治疗晚发性视网膜变性病例中的黄斑新生血管。

目的：描述晚发性视网膜变性患者黄斑新生血管的治疗效果：一名 72 岁的女性患者自数年前开始出现视力下降。该患者曾被诊断为老年性黄斑变性，并接受过抗血管内皮生长因子治疗：视网膜临床检查和超宽视野彩色眼底照片显示，双眼视网膜广泛萎缩。左眼荧光素血管造影显示黄斑新生血管，光学相干断层扫描显示视网膜下积液，彩色眼底照相显示相应出血。阿弗利百普抗血管内皮因子治疗用于治疗左眼黄斑新生血管：我们报告了一例经基因证实的晚发性视网膜变性（一个C1QTN5等位基因中的p.Ser163Arg杂合子致病突变）患者，其视网膜晚期变性并发黄斑新生血管，注射单次阿弗利百普治疗后反应良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊